Stifel raised the price target and maintained a buy rating for XPO, Inc. on August 1, 2025.
2 reports, 1 independent
Updated Aug 1
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Stifel raised the price target and maintained a buy rating for XPO, Inc. on August 1, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Stifel analyst upgraded XPO, Inc. stock rating and price target.1 source
Stifel raised XPO's price target to $145 after peer company results.1 source
Keep exploring
The entities involved
Related events
- Spyre Therapeutics, Inc. was listed on Nasdaq and received analyst ratings from firms including Deutsche Bank and Stifel.
- Stifel reiterated a Buy rating and target price for Spyre Therapeutics, while Deutsche Bank lowered targets following company results.
- Morgan Stanley maintained Equal Weight rating, Stifel lifted target price from $90 to $107, and TD Cowen stuck to its Hold rating for a company (implied to be Elastic).
- Stifel lowered price target on Viking Holdings Ltd, citing European low-water risk. AQR Capital Management led by Cliff Asness tracks the company.
- Stifel upgraded Microsoft's stock rating to Buy from Hold.
Coverage
Newest first; wire copies grouped- StockStoryWhy XPO (XPO) Stock Is Nosediving Shares of freight delivery company XPO (NYSE:XPO) fell 9.1% in the afternoon session after the company reported disappointing second-quarter financial results that r
- StockStoryWhy XPO (XPO) Stock Is Up Today Shares of freight delivery company XPO (NYSE:XPO) jumped 4.3% in the morning session after an analyst at Stifel raised the company's price target to $145 from $135. Th